

Pamela Lawrence Endreny

Partner

pendreny@gibsondunn.com

T: +1 212.351.2474

New York

Pamela Lawrence Endreny is a partner in the New York office of Gibson Dunn and a Co-Chair of the firm's Tax Practice Group.

Pamela represents clients in a broad range of U.S. and international tax matters. Her experience includes mergers and acquisitions, spin-offs, joint ventures, financings, and capital markets transactions. She has obtained private letter rulings from the Internal Revenue Service on tax-free spin-offs and other corporate transactions.

She has been repeatedly selected for inclusion in *Chambers USA: America's Leading Lawyers for Business* and *The Legal 500 US*, and was also named a Tax "MVP" by *Law360*.

Pamela is a member of the Executive Committee of the New York State Bar Association Tax Section. She is also a member of the Tax Forum and Private Investment Fund Tax Forum.

Significant representations include:

- Exxon Mobil Corporation on its redomestication to Texas;
- Merck on its \$9.2 billion acquisition of Cidara Therapeutics, Inc.;
- Modine, in a Reverse Morris Trust, including the spin-off and combination of Modine's Performance Technologies business with Gentherm;
- AT&T in its \$5.75 billion acquisition of substantially all of Lumen's mass markets fiber business;
- Lennar Corporation on the spin-off of Millrose Properties, Inc.;
- VMware in its \$61 billion acquisition by Broadcom;
- The VMware Board Special Committee in Dell Technologies' spin-off of VMware;
- Ziff Davis in its spin-off of Consensus Cloud Solutions, Inc.;
- Wrexham AFC and its owners, Ryan Reynolds and Rob Mac, on Apollo Sports Capital's minority investment in Wrexham AFC;
- A group led by Ryan Reynolds and Hugh Jackman on their acquisition of a controlling stake in Australia's SailGP team, the Bonds Flying Roos;
- Otro Capital on the closing of its inaugural sports buyout fund, Otro Capital Fund I, with \$1.2 billion in committed capital;
- Gyre Therapeutics, Inc., on its acquisition of Cullgen Inc. in an all-stock merger valued at approximately \$300 million;
- 89bio, Inc., on its up to \$3.5 billion sale to Roche Holdings, Inc.;



Capabilities

Tax
Investment Funds
Mergers and Acquisitions
Private Equity

Credentials

Education

Columbia University - 1994 Juris Doctor
Brown University - 1986 Bachelor of Arts

Admissions

New York Bar
Massachusetts Bar

- XOMA Royalty on XenoTherapeutics, Inc. and Xeno Acquisition Corp.'s acquisition of Repare Therapeutics Inc.;
- Arrowhead Pharmaceuticals on an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of Arrowhead.

**Pamela Lawrence
Endreny**
Partner

pendreny@gibsondunn.com

T: +1 212.351.2474

New York